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EWe previously reported stable engraftment in
ogs given 2 Gy total body irradiation (TBI) before
nd short courses of immunosuppression with cyclo-
porine and mycophenolate mofetil [1] or cyclospor-
ne and rapamycin after DLA-identical marrow trans-
lantation [2]. When the TBI dose was lowered to 1
y, uniform graft rejection was seen [1,2].
Stable grafts were also seen in dogs given 4.5 Gy
adiation to the cervical, thoracic, and upper abdominal
ymph node chains [3] and in those that received, in
ddition to 1 Gy TBI, injections of both donor-derived
eripheral blood mononuclear cells (PBMCs) and the
-cell activation blocker CTLA4-immunoglobulin [4].
esults were consistent with the notion that induction
f immunologic host versus donor hyporesponsive-
ess before and administration of a short course of
mmunosuppression after hematopoietic cell trans-
lantation sufﬁced to establish long-term marrow en-
raftment.
In the present study, we substituted the antimetab-
lite methotrexate (MTX) for CTLA4-immunoglobulin
o induce host-versus-graft hyporesponsiveness under
he assumption that host T cells that proliferate in re-
ponse to donor PBMCs would be especially sensitive to
TX. For many years, MTX has been an integral part
f graft-versus-host disease prevention [5-7], and it has
een shown to promote activation-induced cell death [8].
Litters of beagles, mini-mongrel, and golden re-
riever crossbreeds weighing 7.2-11.3 kg were used.
etails on vaccinations, selection of littermate donor-
able 1. Marrow Grafts from DLA-Identical Donors after Donor PBM
Dog No. Marrow Cells (108/kg)
Maximum Don
Granulocytes
G231 7.00 21
G254 2.47 28
G269 2.16 2
G281 2.05 45
G322 7.23 70
G447 3.16 46ecipient pairs by DLA typing, marrow harvest and
njection, postgrafting care, and assessment of engraft-
ent have been described [1,2]. The study was ap-
roved by the Institutional Animal Care and Use
ommittee at the Fred Hutchinson Cancer Research
enter (Seattle, WA), which is accredited by the As-
ociation for Assessment and Accreditation of Labo-
atory Animal Care International.
On days 5 and 3 (day 0 was the day of marrow
ransplantation), dogs received donor PBMCs (5 
06 cells/kg/d intravenously, except for G477 (1 107
ells/kg on day5 only). On days4 and2, 24 hours
fter each PBMC injection, MTX (.4 mg/kg/d) was
dministered intravenously. On day 0, recipients were
iven 1 Gy of TBI at 7 cGy/min from a linear acceler-
tor (CLINAC 4, Varian, Palo Alto, CA). Marrow was
nfused intravenously within hours of TBI (Table 1).
ogs were given cyclosporine, 15 mg/kg twice daily
rally, on days 1 to 35 and mycophenolate mofetil, 10
g/kg twice daily subcutaneously, on days 0 to 27.
Peripheral blood cell changes included moderate
hrombocytopenia, neutropenia, and lymphocytope-
ia (Figure 1; nadir range, days 3-27). Only 1 dog
equired a platelet transfusion. There were no infec-
ions and no graft-versus-host disease. All 6 dogs had
nitial engraftment (Table 1), with maximum donor
himerism levels ranging from 2% to 70% (granulo-
ytes) and 2% to 49% (lymphocytes), respectively.
ventually 4 of the 6 dogs rejected their grafts be-
X, and 1-Gy TBI
merism, %
Graft Rejection
Duration of
Engraftment (wk)onuclear Cells
23 Yes 10
23 Yes 8
2 Yes 5
32 No >26
47 No >26C, MT
or Chi
Mon49 Yes 8
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Letter to the Editor886ween 5 to 10 weeks, whereas 2 dogs had sustained
ngraftment.
Compared with historical controls given neither
onor PBMCs nor MTX [1,2], median duration of
ngraftment in the 6 dogs (9 weeks; P  .3384, log-
ank test) and rate of sustained engraftment (P 
4545, Fisher exact test) showed no statistically signif-
cant difference.
In conclusion, 4 of 6 dogs rejected their marrow
rafts, as evidenced by decreasing donor chimerism
evels, within a time frame that was similar to that seen
n previously published controls [1,2], and only 2 of the
had sustained engraftment. Clearly, the degree of host-
ersus-graft hyporesponsiveness achieved with MTX
as less than previously accomplished with T-cell co-
timulatory blockade through CTLA4-immunoglobulin
4]. Whether MTX will be useful when combined with
-cell costimulatory blockade or immunosuppressive
rugs with a different mechanism of action, for example,
apamycin, remains to be investigated.
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